Compound class:
Synthetic organic
Comment: KSP-1007 is a bicyclic boronic acid β-lactamase inhibitor (BLI), with broad-spectrum activity against both serine and metallo-β-lactamases, discovered through a collaboration between the Kitasato Institute (Tokyo, Japan) and Sumitomo Pharma (Osaka, Japan) [1]. KSP-1007, in combination with meropenem, is under clinical development for the treatment of infections caused by carbapenem-resistant bacterial infections.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
7-({1-[(2R)-2-amino-2-(1H-imidazol-4-yl)acetyl]azetidin-3-yl}oxy)-2-hydroxy-3,4-dihydro-2H-1,2-benzoxaborinine-8-carboxylic acid |
Database Links ![]() |
|
Specialist databases | |
Antibiotic DB
![]() |
KSP-1007+meropenem |
Other databases | |
CAS Registry No. | 2380240-20-8 (source: Scifinder) |
GtoPdb PubChem SID | 500839957 |
PubChem CID | 149866877 |
Search Google for chemical match using the InChIKey | CAHUDGVGUAJGGS-CQSZACIVSA-N |
Search Google for chemicals with the same backbone | CAHUDGVGUAJGGS |
UniChem Compound Search for chemical match using the InChIKey | CAHUDGVGUAJGGS-CQSZACIVSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | CAHUDGVGUAJGGS-CQSZACIVSA-N |